Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
3.000
+0.100 (3.45%)
At close: Jul 2, 2026, 4:00 PM EDT
2.990
-0.010 (-0.33%)
After-hours: Jul 2, 2026, 4:10 PM EDT
Genelux Employees
As of December 31, 2025, Genelux had 26 total employees, including 25 full-time and 1 part-time employees. The number of employees increased by 2 or 8.33% compared to the previous year.
Employees
26
Change
2
Growth
8.33%
Revenue / Employee
$308
Profits / Employee
-$1,291,577
Market Cap
132.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 26 | 2 | 8.33% | 25 | 1 |
| Mar 31, 2025 | 24 | 1 | 4.35% | 24 | 0 |
| Dec 31, 2024 | 24 | 1 | 4.35% | 24 | 0 |
| Sep 30, 2024 | 25 | 3 | 13.64% | 25 | 0 |
| Jun 30, 2024 | 24 | 4 | 20.00% | 24 | 0 |
| Mar 31, 2024 | 23 | 8 | 53.33% | 23 | 0 |
| Dec 31, 2023 | 23 | 8 | 53.33% | 23 | 0 |
| Sep 30, 2023 | 22 | 7 | 46.67% | 22 | 0 |
| Jun 30, 2023 | 20 | 6 | 42.86% | 20 | 0 |
| Mar 31, 2023 | 15 | 1 | 7.14% | 15 | 0 |
| Dec 31, 2022 | 15 | 1 | 7.14% | 15 | 0 |
| Sep 30, 2022 | 15 | - | - | 15 | 0 |
| Jun 30, 2022 | 14 | 1 | 7.69% | 14 | 0 |
| Mar 31, 2022 | 14 | 1 | 7.69% | 14 | 0 |
| Mar 31, 2021 | 13 | - | - | 13 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Fractyl Health | 100 |
| Agenus | 81 |
| PepGen | 59 |
| Aardvark Therapeutics | 40 |
| Enlivex | 34 |
| Cue Biopharma | 29 |
| Spero Therapeutics | 25 |
GNLX News
- 2 days ago - Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - GlobeNewsWire
- 16 days ago - Genelux Transcript: AGM 2026 - Transcripts
- 2 months ago - Genelux reports Q1 EPS (20c), consensus (19c) - TheFly
- 2 months ago - Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Genelux Quarterly report: Q1 2026 - Filings
- 2 months ago - Genelux Earnings release: Q1 2026 - Filings
- 2 months ago - Genelux Slides: Corporate presentation - Filings
- 2 months ago - Genelux Proxy statement: Proxy filing - Filings